Laxxon Medical
Company
As of November 2026
Laxxon Medical Corp. is a privately held drug development company with headquarters in New York and research and development in Jena, Germany.
Leadership

Helmut Kerschbaumer
CEO and Chairman
Helmut Kerschbaumer trained in retail distribution at C&A in Germany and went on to join the management board of C&A Austria.
After 15 years in retail, he was appointed Managing Director of Melbrosin International, an international pharmaceutical distributor, which he acquired in a management buyout in 2000 and later sold to BioProgress plc (UK). He also spent two years as a director of a UK-listed pharmaceutical company.
From 2012 to 2016 he was CEO of IPMD GmbH, and from 2013 to 2017 director and CEO of ULURU Inc. (USA).

Klaus Kühne
Chief Operating Officer
Klaus Kühne is a lawyer with more than 25 years of experience in the pharmaceutical industry and expertise in managing product development, global commercialization, marketing and operations.
He took part in the management buyout of the pharmaceutical company Melbrosin and its subsequent sale to BioProgress, a publicly listed British pharmaceutical and medical devices company, where he served as an executive director until 2009.
He also served on the board of directors of ULURU, a US specialty pharmaceutical company, where he was responsible for business development and product commercialization.
In 2017 he founded Laxxon Medical with his business partners Helmut Kerschbaumer and Dr. Achim Schneeberger, when they acquired the license for pharmaceutical applications of the technology behind SPID®.

Alexander Ruckdaeschel
Chief Strategy Officer
Alexander Ruckdaeschel has worked in the financial industry in the United States and Europe since 2001, as a co-founder, partner and senior manager.
He was a manager at DAC-FUNDS, a family office focused on small-cap private and publicly listed companies worldwide. From 2002 to 2006 he was a partner at Nanostart AG, a publicly listed private equity group focused on nanotechnology, where he headed its US group. He has significant experience in start-up operations as a founder and co-founder. After serving in the German military and in international United Nations operations, he was a research assistant at Dunmore Management in New York, where he focused on intrinsic value, identifying undervalued companies with global scale potential.
He serves on the boards of several private and public companies in different industries, including Electronic Recyclers International, Vuzix Corporation, PainQX, Tellus Therapeutics, Simple Kneads, Emspire-Group and Kinoemen Group.

Achim Schneeberger, MD
Chief Scientific Officer
Achim Schneeberger holds an MD from the University of Tübingen, Germany, and began his medical career at the Medical University of Vienna. He has more than 20 years of experience in biomedical research and drug development, with a focus on cancer and chronic diseases. After a research stay at Washington University in St. Louis, USA, he joined AFFiRiS AG, an Austrian vaccine developer.
From 2006 to 2016 he built up the clinical research department at AFFiRiS and, as Chief Medical Officer, was responsible for all of the company's clinical programs. Under his leadership, the company conducted 19 Phase 1 and Phase 2 studies in Alzheimer's disease, Parkinson's disease, multiple system atrophy and atherosclerosis.
Board of Directors





Michael A. Stebler
Non-executive Director
Read bio
Michael A. Stebler has served on the Board of Directors of Laxxon Medical Corp. since 2026. He works closely with the CEO and the COO on corporate strategy.
He brings more than 25 years of experience in senior management positions at Swisscom Mobile, Credit Suisse and UBS. He holds master's degrees from the University of Rochester and the University of Bern.
- NU
Nneka Ukpai
Independent Non-executive Director
Read bio
Nneka Ukpai is a financial technology innovator working with Pop Venture to democratize access to private capital markets. She previously served as Head of Financial Innovation at Better, a homeownership platform that has surpassed $100 billion in funded volume.
Before Better, she was a senior attorney at a global law firm, where she helped C-suite executives navigate global regulatory and enforcement actions. She is a graduate of Howard University and Harvard Law School, where she serves on the teaching faculty of the Trial Advocacy Workshop. Her focus on driving growth while mitigating business risk has made her a trusted advisor to CEOs and led her to serve on several private boards.
Scientific Advisory Board
- USS
Ulrich S. Schubert, PhD
Scientific Advisory Board
Dr. Schubert is a chemist and professor of organic and macromolecular chemistry at Friedrich Schiller University Jena. He studied chemistry at the universities of Frankfurt am Main and Bayreuth and at Virginia Commonwealth University (Richmond, USA), and received his doctorate from the University of Bayreuth with a joint PhD thesis with the University of South Florida (Tampa, USA). He did postdoctoral research with Jean-Marie Lehn, winner of the 1987 Nobel Prize in Chemistry, and completed his habilitation at the Technical University of Munich. His research focuses on innovative and sustainable polymers with potential applications in the life sciences, such as medicine, and in energy storage and conversion. He was an associate professor at the Center for NanoScience of Ludwig Maximilian University of Munich before receiving a Heisenberg fellowship from the German Research Foundation, which he held at the Technical University of Munich. From 2000 to 2007 he was professor of macromolecular chemistry and nanoscience at Eindhoven University of Technology, and from 2003 to 2014 scientific chairman of the HTE division of the Dutch Polymer Institute. From 2007 to 2010 he held a part-time professorship at Eindhoven while taking up a full professorship of organic and macromolecular chemistry at Friedrich Schiller University Jena.
Since 2007 he has held various positions at Friedrich Schiller University Jena, including director of the Laboratory of Organic and Macromolecular Chemistry, spokesperson of the research focus "Innovative Materials and Technologies," and Vice Dean and Dean of the Faculty of Chemistry and Earth Sciences. He is the founding director of the Jena Center for Soft Matter and of the Center for Energy and Environmental Chemistry Jena. He has initiated seven spin-offs and two further company formations and is a founding ambassador of the university's K1 Gründerservice (start-up service). He holds 52 patents and patent applications, 35 of which have been transferred to industry. He is a member of the international advisory boards of ten scientific journals and guest editor of 14 special issues or books and four specialized textbooks. He has more than 1,200 peer-reviewed publications, 87,000 citations and an h-index of 130 (Google Scholar). In 2022 he was awarded an ERC Advanced Grant (EUR 2.5 million).
- UG
Ulrich Granzer, PhD
Scientific Advisory Board
Dr. Granzer qualified as a pharmacist at the University of Marburg in 1984 and went on to doctoral studies, during which he also lectured in pharmaceutical chemistry. In 1988 he served in the German Air Force, reaching the rank of captain with responsibility for drug safety. In 1989 he began his industry career in the Regulatory Affairs department at Glaxo and was appointed Director of Regulatory Affairs in 1993. He then served on the Global Regulatory Board of Glaxo and later Glaxo Wellcome, and during this time led a company-wide reengineering project at Glaxo Germany.
In 1998 he joined BASF Pharma (Knoll) as Vice President of Global Regulatory Centres, with global responsibility for regulatory affairs, drug safety and GxP in drug development. At Knoll he was responsible for the development of small molecules and several biologics in stroke, septic shock and rheumatoid arthritis, and he played a key role in the program for the first fully human anti-TNF antibody, now marketed as Humira®. After Abbott took over Knoll, he joined Bayer as Vice President Global Regulatory Affairs, responsible for all regulatory aspects of development and submission projects worldwide. In early 2002 he founded his own company, Granzer Regulatory Consulting & Services.
- KvS
Kurt Van Scoik, PhD
Scientific Advisory Board
Dr. Van Scoik studied pharmacy and received his doctorate in pharmaceutics from the University of Wisconsin-Madison in 1987. He spent ten years at Abbott Laboratories in the Pharmaceutical Products Division, solving problems in the development of new drugs and new solid dosage forms, including stability, bioavailability and processing, from initial formulation through scale-up. In 1997 he left Abbott as Senior CMC Project Manager to become Senior Director of Pharmaceutical R&D and New Technologies at Schering-Plough Corporation, where he led the launch of more than 60 new products, including tablets, softgels, dermatological products, oral liquids and aerosols.
In 2004 he joined Eli Lilly and Company as Director of Manufacturing Science and Technology, providing scientific, technical and regulatory support for solid oral dosage form products to Lilly manufacturing sites worldwide, as well as technical guidance for new products in development. He then moved to Lilly Research Laboratories, where he provided scientific and technical leadership for new drug products, new technology platforms and drug delivery, and supported other Lilly functions, until he retired in February 2023 as Associate Vice President in synthetic molecule design and development. He has also served as an expert witness in several litigation cases.
- US
Urs Spitz, PhD
Scientific Advisory Board
Dr. Urs Spitz is a life sciences entrepreneur, investor and strategic advisor with extensive experience across pharmaceuticals, biotechnology, diagnostics and life science tools.
He helped build Biosynth into a global life science company and brings Laxxon expertise in scientific translation, commercialization strategy, corporate development and the scaling of technology-driven healthcare businesses.
Company facts
- Headquarters
- 261 Madison Avenue, 9th Floor, New York, NY 10016, USA
- Research and development
- Laxxon Medical GmbH, Otto-Schott-Straße 15, 07745 Jena, Germany
- Intellectual property
- Laxxon's IP is continuously growing, and together with the licensed IP from Exentis Group, consists of 230 patents and patent applications with more than 5,500 patent claims.
Frequently asked questions
What does Laxxon Medical do?
Laxxon Medical is a drug development company. It develops oral medicines designed to make treatment simpler for patients, led by an oral GLP-1 RA, and partners with pharma companies on development and licensing.
What is SPID®?
SPID® (Screen Printed Innovative Drug) is a cold-process screen printing platform for oral dosage forms. It prints tablets layer by layer, with layers of 10 to 150 microns, and builds defined internal structures.
What can SPID® do?
SPID® enables tailored release profiles, combinations of several active ingredients in a single dosage form and a defined, heterogeneous distribution of active ingredients within the tablet.
Why an oral GLP-1 RA?
Most GLP-1 RA medicines are peptides, and peptide medicines usually have to be injected because the gastrointestinal tract poses substantial barriers to oral delivery. With LXM.2, Laxxon is developing SPID®-printed oral GLP-1 RA microtablets; Phase 1 is planned for 2027.
Where does the pipeline stand?
Laxxon's focus program is LXM.2, an oral GLP-1 RA, with Phase 1 planned for 2027. LXM.5 for Parkinson's disease is in preparation for Phase 1, with first dosing planned for early 2027. LXM.8, a partner program, completed Phase 1 in August 2025. Six further programs are in preclinical development.
How large is the patent portfolio?
Including in-licensed rights, Laxxon's portfolio comprises more than 230 patents and patent applications, with terms potentially extending into 2046 (company figures, as of November 2026).
What rights does Laxxon hold to SPID®?
Laxxon holds its own patents, such as US 11,419,824 B2. Since 2017, Laxxon has held the exclusive worldwide license from Exentis Group AG and Exentis Knowledge GmbH for pharmaceutical applications of the technology behind SPID®.
Is Laxxon a contract manufacturer?
No. Laxxon is a drug development company and does not offer contract manufacturing. It prints development batches at its research and development site in Jena, Germany; clinical-scale cGMP manufacturing for its programs is being established with CDMO partner Adare Pharma Solutions in Pessano (Milan), Italy.
Which regulatory pathways does Laxxon use?
Laxxon develops its programs for the FDA 505(b)(2) pathway in the US and the hybrid application under Article 10(3) of Directive 2001/83/EC in the EU.
How can a pharma company work with Laxxon?
Through licensing or co-development of Laxxon's pipeline assets, development projects with SPID®, or lifecycle management of established products.
Is Laxxon publicly listed?
No. Laxxon Medical Corp. is privately held.
Who owns Laxxon Medical?
Laxxon Medical Corp. is an independent, privately held company headquartered in New York. It is not a subsidiary of Xlife Sciences AG or of any other company, and Xlife Sciences AG holds no shares in Laxxon.
How is Laxxon financed?
Since its founding in 2017, Laxxon has been financed by private and institutional investors. Shareholders receive a company update twice a year. Qualified investors can request company documents from investor relations.
